Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Codexis stock

CDXS
US1920051067
A0Q2S4

Price

3.98
Today +/-
+0.09
Today %
+2.53 %
P

Codexis stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Codexis stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Codexis stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Codexis stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Codexis's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Codexis Stock Price History

DateCodexis Price
11/18/20243.98 undefined
11/15/20243.88 undefined
11/14/20243.74 undefined
11/13/20244.06 undefined
11/12/20244.02 undefined
11/11/20244.06 undefined
11/8/20244.08 undefined
11/7/20244.18 undefined
11/6/20244.01 undefined
11/5/20243.82 undefined
11/4/20243.49 undefined
11/1/20243.50 undefined
10/31/20243.14 undefined
10/30/20243.21 undefined
10/29/20243.19 undefined
10/28/20243.18 undefined
10/25/20242.91 undefined
10/24/20242.99 undefined
10/23/20243.06 undefined
10/22/20243.30 undefined
10/21/20243.29 undefined

Codexis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Codexis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Codexis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Codexis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Codexis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Codexis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Codexis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Codexis’s growth potential.

Codexis Revenue, EBIT and net profit per share

DateCodexis RevenueCodexis EBITCodexis Net Income
2029e180.72 M undefined0 undefined-15.77 M undefined
2028e147.07 M undefined17.49 M undefined-830,076 undefined
2027e117.52 M undefined-397,116.6 undefined-10.79 M undefined
2026e82.84 M undefined-21.93 M undefined-39.84 M undefined
2025e67.94 M undefined-52.54 M undefined-57.04 M undefined
2024e66.6 M undefined-56.67 M undefined-65.89 M undefined
202370.14 M undefined-54.8 M undefined-76.24 M undefined
2022138.6 M undefined-31.7 M undefined-33.6 M undefined
2021104.8 M undefined-22.7 M undefined-21.3 M undefined
202069.1 M undefined-23.9 M undefined-24 M undefined
201968.5 M undefined-12.5 M undefined-11.9 M undefined
201860.6 M undefined-11.3 M undefined-10.9 M undefined
201750 M undefined-23 M undefined-23 M undefined
201648.8 M undefined-8.6 M undefined-8.6 M undefined
201541.8 M undefined-7.8 M undefined-7.6 M undefined
201435.3 M undefined-19.1 M undefined-19.1 M undefined
201331.9 M undefined-40.3 M undefined-41.3 M undefined
201288.3 M undefined-27.5 M undefined-30.9 M undefined
2011123.9 M undefined-15.9 M undefined-16.6 M undefined
2010107.1 M undefined-7.1 M undefined-8.5 M undefined
200982.9 M undefined-18.4 M undefined-20.3 M undefined
200850.5 M undefined-44 M undefined-45.1 M undefined
200725.3 M undefined-38.3 M undefined-39 M undefined
200612.1 M undefined-18.8 M undefined-18.7 M undefined
200511.8 M undefined-11.2 M undefined-11.6 M undefined
20044.9 M undefined-13.2 M undefined-14.3 M undefined

Codexis Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
4111225508210712388313541485060686910413870666782117147180
-175.009.09108.33100.0064.0030.4914.95-28.46-64.7712.9017.1417.074.1720.0013.331.4750.7232.69-49.28-5.711.5222.3942.6825.6422.45
100.0081.8283.3368.0074.0080.4973.8366.6764.7754.8471.4385.3781.2570.0080.0076.4779.7178.8572.4681.4386.3685.0769.5148.7238.7831.67
491017376679825717253539354852558210057000000
-14-11-18-39-45-20-8-16-30-41-19-7-8-23-10-11-24-21-33-76-65-57-39-100-15
--21.4363.64116.6715.38-55.56-60.00100.0087.5036.67-53.66-63.1614.29187.50-56.5210.00118.18-12.5057.14130.30-14.47-12.31-31.58-74.36--
1.11.51.11.72.42.624.635.736.838.238.239.440.646.252.256.559.464.665.368.13000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Codexis Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Codexis is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
32.284.137.155.672.453.545.525.126.523.319.231.25390.5150.1116.811465.12
2.86.46.27.215.318.97.55.43.97.35.911.813.520.229.337.740.919.93
000000000000000000
0.71.632.92.84.51.31.51.410.810.60.411.222.69
0.72.82.11.71.62.35.43.81.31.21.211.13.246.365.74
36.494.948.467.492.179.259.735.833.132.827.14568.2114.3184.4162162.993.47
4.511.11621.621.524.216.78.443.12.22.84.830.431.265.561.928.62
00001.710.33.60.80.71.51.10.70.601.51420.59.7
000000000000000000
2.32.81.80.920.216.412.99.66.22.800000000
1.93.13.13.23.23.23.23.23.23.23.23.23.23.23.23.23.22.46
1.31.71.65.92.62.53.7111.11.91.92.51.21.41.81.92.31
1018.722.531.649.256.640.12315.111.78.48.611.134.837.384.587.543.1
46.4113.670.999141.3135.899.858.848.244.535.553.679.3149.1221.7246.5250.4136.56
                                   
77.5132.7132.7179.700000000000000.01
2.56.210.115275.5287.8294.1298.4302.4306311.2340.1386.8447.9536.5552.1566.1584.14
-55.2-94.2-139.3-159.6-168.1-184.7-215.6-256.9-275.9-283.5-292.1-315.1-330.5-342.4-366.4-387.7-421.3-497.53
-100500100-3000-400-1000-1004000-500000000
000000000000000000
24.745.23.634.8107.4102.778.441.526.422.919.124.556.3105.5170.1164.4144.886.62
3.11212.611.39.210.43.744.73.44.23.53.12.6333.25.95
4.110.712.616.913.714.110.45.25.65.35.88.49.412.720.227.832.119.76
4.35.510.615.44.53.82.223.56.12.3135.70.11.82.613.710.12
0.61.51.4200000000000000
1.64.55.25.40000000000.10000
13.734.242.45127.428.316.311.213.814.812.324.918.215.52533.44935.83
2.512.98.52.600000000.30.100000
000000000000000000
5.521.216.410.76.54.95.26.28.16.94.23.84.828.226.648.656.514.12
834.124.913.36.54.95.26.28.16.94.24.14.928.226.648.656.514.12
21.768.367.364.333.933.221.517.421.921.716.52923.143.751.682105.549.95
46.4113.570.999.1141.3135.999.958.948.344.635.653.579.4149.2221.7246.4250.3136.56
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Codexis provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Codexis's financial health and stability.

Assets

Codexis's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Codexis must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Codexis after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Codexis's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
-11-18-38-45-20-8-16-30-41-19-7-8-23-10-11-24-21-33-76
2224681112106541112355
0000000000000000000
422610-26-5-116-3-36-12-12-3-721-18
004611191913101191113151717233246
0001,0001,00000000000000000
0000000000000000000
-4-13-6-36-8-160-11-2300-1-8-14-12-16-1411-52
-2-1-8-8-10-6-10-2-10-100-2-3-3-13-8-4
30-397-20-5-4816134-100-2-3-5-21-13-4
51-3015-101-381914400000-2-7-50
0000000000000000000
0413-4-6-80000000000000
035550477421000124425787509
03968-340622100-1021385380308
------3.00-----1.00-1.00-2.00-3.00-2.00-6.00-1.00-1.00-
0000000000000000000
02622-33940-466-94-3-311213758-31-2-49
-6.39-14.39-14.72-44.86-19.49-23.37-11.23-14.82-24.180.02-1.63-2.75-9.75-16.86-16.29-20.21-28.12.97-57.06
0000000000000000000

Codexis stock margins

The Codexis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Codexis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Codexis.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Codexis's sales revenue. A higher gross margin percentage indicates that the Codexis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Codexis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Codexis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Codexis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Codexis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Codexis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Codexis Margin History

Codexis Gross marginCodexis Profit marginCodexis EBIT marginCodexis Profit margin
2029e81.74 %0 %-8.73 %
2028e81.74 %11.89 %-0.56 %
2027e81.74 %-0.34 %-9.18 %
2026e81.74 %-26.48 %-48.1 %
2025e81.74 %-77.33 %-83.95 %
2024e81.74 %-85.09 %-98.93 %
202381.74 %-78.13 %-108.69 %
202272.58 %-22.87 %-24.24 %
202178.72 %-21.66 %-20.32 %
202080.03 %-34.59 %-34.73 %
201977.08 %-18.25 %-17.37 %
201879.21 %-18.65 %-17.99 %
201771.4 %-46 %-46 %
201680.12 %-17.62 %-17.62 %
201584.21 %-18.66 %-18.18 %
201472.52 %-54.11 %-54.11 %
201354.55 %-126.33 %-129.47 %
201265.35 %-31.14 %-34.99 %
201166.26 %-12.83 %-13.4 %
201073.86 %-6.63 %-7.94 %
200979.86 %-22.2 %-24.49 %
200873.86 %-87.13 %-89.31 %
200767.19 %-151.38 %-154.15 %
200685.12 %-155.37 %-154.55 %
200581.36 %-94.92 %-98.31 %
2004100 %-269.39 %-291.84 %

Codexis Stock Sales Revenue, EBIT, Earnings per Share

The Codexis earnings per share therefore indicates how much revenue Codexis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Codexis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Codexis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Codexis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Codexis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Codexis Revenue, EBIT and net profit per share

DateCodexis Sales per ShareCodexis EBIT per shareCodexis Earnings per Share
2029e2.22 undefined0 undefined-0.19 undefined
2028e1.81 undefined0 undefined-0.01 undefined
2027e1.44 undefined0 undefined-0.13 undefined
2026e1.02 undefined0 undefined-0.49 undefined
2025e0.83 undefined0 undefined-0.7 undefined
2024e0.82 undefined0 undefined-0.81 undefined
20231.03 undefined-0.8 undefined-1.12 undefined
20222.12 undefined-0.49 undefined-0.51 undefined
20211.62 undefined-0.35 undefined-0.33 undefined
20201.16 undefined-0.4 undefined-0.4 undefined
20191.21 undefined-0.22 undefined-0.21 undefined
20181.16 undefined-0.22 undefined-0.21 undefined
20171.08 undefined-0.5 undefined-0.5 undefined
20161.2 undefined-0.21 undefined-0.21 undefined
20151.06 undefined-0.2 undefined-0.19 undefined
20140.92 undefined-0.5 undefined-0.5 undefined
20130.84 undefined-1.05 undefined-1.08 undefined
20122.4 undefined-0.75 undefined-0.84 undefined
20113.47 undefined-0.45 undefined-0.46 undefined
20104.35 undefined-0.29 undefined-0.35 undefined
200931.88 undefined-7.08 undefined-7.81 undefined
200821.04 undefined-18.33 undefined-18.79 undefined
200714.88 undefined-22.53 undefined-22.94 undefined
200611 undefined-17.09 undefined-17 undefined
20057.87 undefined-7.47 undefined-7.73 undefined
20044.45 undefined-12 undefined-13 undefined

Codexis business model

Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.com.

Codexis SWOT Analysis

Strengths

Codexis Inc has a strong and experienced management team, enabling effective decision-making and business strategy implementation. The company possesses cutting-edge biotechnology expertise, allowing it to develop innovative and high-quality products. Codexis also has a strong intellectual property portfolio, which provides a competitive advantage in the industry.

Weaknesses

One of the weaknesses of Codexis Inc is its high dependence on a limited number of key customers. This reliance creates vulnerability in case of any disruptions or changes in customers' preferences. The company also faces challenges in effectively managing its research and development costs, as developing new products requires substantial investments.

Opportunities

Codexis Inc has significant opportunities for growth in the expanding biotechnology and pharmaceutical markets. The increasing demand for sustainable and environmentally friendly solutions presents a favorable market for Codexis' biocatalysis technology. The company can also explore strategic partnerships and collaborations to expand its market reach and access new customers.

Threats

One of the potential threats for Codexis Inc is intense competition in the biotechnology industry. Rival companies with similar technologies and product offerings may limit the market share of Codexis. The company also faces regulatory risks, as changes in government regulations and policies related to biotechnology can impact its operations. Additionally, macroeconomic factors such as economic downturns can affect customer spending and demand for Codexis' products.

Codexis Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Codexis Revenue by Segment

Segmente20222021202020192018
Research and Development Revenues---38.99 M USD35 M USD
Product Sales----22.17 M USD
Research and development revenue--20.95 M USD--
Research and development revenue ($1,245, $1,955 and $900 from a related party)11.98 M USD----
Research and development revenue ($0, $1,245 and $1,955 from a related party)-----
Product revenue ($0, $514 and $0 from a related party)-----
Product revenue ($514, $0 and $0 from a related party)-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Codexis Revenue by Segment

Segmente20222021202020192018
Research and Development Revenues---38.99 M USD33.4 M USD
Product revenue-70.66 M USD---
Research and development revenue--38.84 M USD--
Research and development revenue ($1,955, $900 and $0 from a related party)-34.1 M USD---
Product Sales---29.47 M USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Codexis Revenue by Segment

Segmente20222021202020192018
Research and development revenue-34.1 M USD---
Revenue sharing arrangement-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Codexis Revenue by Segment

Segmente20222021202020192018
Performance Enzymes126.61 M USD90.52 M USD48.11 M USD-47.07 M USD
Novel Biotherapeutics11.98 M USD14.24 M USD20.95 M USD-13.52 M USD

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Codexis Revenue by Segment

Segmente20222021202020192018
Performance Enzymes---58.16 M USD-
Novel Biotherapeutics---10.3 M USD-

Codexis Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Codexis Revenue by Segment

DateAmericasAPACCHINAEMEAEuropeIndiaIRELANDOther Asian CountriesOthersRest of worldSingaporeSwitzerlandSWITZERLANDUnited KingdomUnited States
202313.73 M USD33.5 M USD20.3 M USD22.91 M USD--500,000 USD-----11.1 M USD-13.7 M USD
202217 M USD65.05 M USD-56.54 M USD-----------
202123.48 M USD61.09 M USD-20.19 M USD-----------
202024.35 M USD25.45 M USD-19.26 M USD-----------
201913.04 M USD18.29 M USD-37.13 M USD-----------
201815.33 M USD22.86 M USD-8.88 M USD-----------
2017-----5.64 M USD---9.48 M USD6.17 M USD13.22 M USD-51,000 USD15.47 M USD
2016----17.14 M USD3.58 M USD-1.16 M USD1.82 M USD-3.84 M USD---21.31 M USD
2015----14.15 M USD1.03 M USD-864,000 USD5,000 USD-963,000 USD---24.8 M USD
2014----15.07 M USD919,000 USD-1.64 M USD113,000 USD-1.44 M USD---16.14 M USD
201251.71 M USD---11.15 M USD16.81 M USD--1.11 M USD-7.51 M USD----
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Codexis Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Codexis historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Codexis shares outstanding

The number of shares was Codexis in 2023 — This indicates how many shares 68.131 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Codexis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Codexis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Codexis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Codexis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Codexis.

Codexis latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.24 -0.29  (-19.1 %)2024 Q3
6/30/2024-0.27 -0.32  (-18.96 %)2024 Q2
3/31/2024-0.18 -0.16  (12.85 %)2024 Q1
12/31/2023-0.13 -0.1  (21.14 %)2023 Q4
9/30/2023-0.33 -0.5  (-51.15 %)2023 Q3
6/30/2023-0.22 -0.17  (22.02 %)2023 Q2
3/31/2023-0.32 -0.34  (-7.8 %)2023 Q1
12/31/2022-0.23 -0.14  (39.39 %)2022 Q4
9/30/2022-0.19 -0.15  (20.84 %)2022 Q3
6/30/2022-0.14 -0.04  (70.89 %)2022 Q2
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Codexis stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

63

👫 Social

96

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Codexis shareholders

%
Name
Stocks
Change
Date
9.95331 % Casdin Capital, LLC8,100,0006,100,0009/20/2024
9.42492 % Opaleye Management Inc.7,670,0004,130,0009/25/2024
6.35304 % BlackRock Institutional Trust Company, N.A.5,170,105161,3946/30/2024
5.14168 % Fidelity Management & Research Company LLC4,184,30311,6096/30/2024
5.02732 % The Vanguard Group, Inc.4,091,230-166,9716/30/2024
4.46009 % Nantahala Capital Management, LLC3,629,622-832,2566/30/2024
3.32858 % Baillie Gifford & Co.2,708,802-736,5076/30/2024
3.31336 % Telemark Asset Management, LLC2,696,41106/30/2024
2.46098 % Columbia Threadneedle Investments (US)2,002,745703,6726/30/2024
2.27124 % Nuveen LLC1,848,338215,7656/30/2024
1
2
3
4
5
...
10

Codexis Executives and Management Board

Dr. Stephen Dilly(63)
Codexis President, Chief Executive Officer, Director (since 2020)
Compensation 5.89 M
Mr. Kevin Norrett(50)
Codexis Chief Operating Officer
Compensation 2.28 M
Ms. Margaret Fitzgerald(52)
Codexis Chief Legal and Compliance Officer, General Counsel and Secretary
Compensation 2.18 M
Mr. Byron Dorgan(80)
Codexis Independent Chairman of the Board
Compensation 221,660
Dr. Rahul Singhvi(58)
Codexis Independent Director
Compensation 217,956
1
2
3

Most common questions regarding Codexis

What values and corporate philosophy does Codexis represent?

Codexis Inc represents a strong commitment to innovation and sustainability in the biotechnology industry. The company's corporate philosophy is centered around delivering transformative solutions for its customers and creating value for its stakeholders. Codexis Inc is dedicated to leveraging its proprietary technologies and expertise to develop and commercialize high-performance enzymes and other bio-based products. By harnessing the power of biocatalysis, the company aims to enable more sustainable manufacturing processes across various sectors. Codexis Inc's steadfast dedication to excellence and its focus on delivering sustainable solutions makes it a prominent player in the biotechnology industry.

In which countries and regions is Codexis primarily present?

Codexis Inc is primarily present in the United States.

What significant milestones has the company Codexis achieved?

Codexis Inc has achieved several significant milestones throughout its history. One notable achievement was the commercialization of its proprietary CodeEvolver® protein engineering platform. This innovation enabled the company to develop and optimize bio-based processes for various industries, including pharmaceuticals, food and beverages, and chemicals. Another milestone was when Codexis partnered with leading companies like Merck, GlaxoSmithKline, and Shell, showcasing its reputation as a trusted collaborator. Additionally, the company's successful initial public offering (IPO) in 2010 marked a major milestone, providing Codexis with the financial resources to further expand its cutting-edge biocatalysis technologies. Overall, Codexis Inc has consistently demonstrated industry leadership and achieved significant progress in advancing sustainable solutions.

What is the history and background of the company Codexis?

Codexis Inc is a leading protein engineering company based in Redwood City, California. Founded in 2002, Codexis specializes in designing and optimizing enzymes for various industries, including pharmaceuticals, food and beverages, and sustainable chemistry. With a strong focus on biocatalysis, the company utilizes its proprietary CodeEvolver® platform to develop customized enzyme solutions that enhance the manufacturing processes of its clients. Over the years, Codexis has established itself as a key player in the biotech industry, collaborating with global partners and attracting numerous high-profile clients. By leveraging its expertise in directed evolution and protein engineering, Codexis continues to drive innovation and provide sustainable solutions to address complex challenges in different sectors. As a leader in the field, Codexis Inc consistently strives to deliver value and impact through the application of biocatalysis and its cutting-edge enzyme technologies.

Who are the main competitors of Codexis in the market?

The main competitors of Codexis Inc in the market include companies such as DSM, Ginkgo Bioworks, and Amyris.

In which industries is Codexis primarily active?

Codexis Inc is primarily active in the biotechnology industry.

What is the business model of Codexis?

The business model of Codexis Inc is focused on providing sustainable biocatalysis solutions to industries such as pharmaceuticals, food and beverage, and chemicals. Codexis employs proprietary protein engineering technology to create highly efficient biocatalysts that can replace traditional chemical processes, resulting in cost savings, increased product yields, and reduced environmental impact. By collaborating with its customers, Codexis develops customized enzymes and processes that address specific challenges and improve overall efficiency in various manufacturing processes. Codexis aims to offer value-added solutions to help its customers achieve their sustainability goals while maintaining profitability.

What is the P/E ratio of Codexis 2024?

The Codexis P/E ratio is -4.11.

What is the P/S ratio of Codexis 2024?

The Codexis P/S ratio is 4.07.

What is the Quality Investing of Codexis?

The Quality Investing for Codexis is 3/10.

What is the revenue of Codexis 2024?

The expected Codexis revenue is 66.6 M USD.

How high is the profit of Codexis 2024?

The expected Codexis profit is -65.89 M USD.

What is the business model of Codexis

Codexis Inc. is a specialist in enzyme technology, operating since 2002 and based in Redwood City, California. The company's business model includes three main areas: enzyme development, proteins, and research services. By combining its capabilities in enzyme technology and protein engineering, Codexis has created unique solutions tailored to the needs of the biotechnology, chemical, pharmaceutical, and food industries. The core business of Codexis is enzyme development. Codexis manufactures enzymes that help customers improve chemical processes by exhibiting higher activities and selectivities, making the production of chemicals and bioproducts more cost-effective and environmentally friendly. The company has developed a range of enzymes used in industrial biotechnology, including medicines, seed treatments, food and feed additives, as well as detergents and cleaning agents. In addition to enzyme development, Codexis also offers proteins that the company uses for biochemical analysis, diagnostics, and protein production. Another business area of Codexis is the manufacturing of enzymes for use in IVD diagnostics. These enzymes are used in medicine and biotechnology, particularly in clinical diagnostics and quality assurance. Codexis also provides research services based on enzyme and protein engineering solutions. The company's research department specializes in developing high-performance enzymes and proteins that enable a variety of applications. Furthermore, Codexis utilizes its research capabilities to offer contract research services in protein engineering and expression, as well as enzyme screening and optimization. Codexis has also developed fluorescence spectroscopy technology that allows for the real-time measurement of enzyme activity. These advanced enzyme engineering tools are essential for customers looking to optimize their processes and improve cost-effectiveness. In terms of its business model, Codexis generates its revenues primarily through the sale of enzyme products and contract research services. The company also pursues licensing revenue for its technology related to the development and use of enzymes in the industry. The company is committed to maintaining and expanding its competitive position in the field of enzyme and protein engineering technology. Codexis continuously strives to develop promising technologies for its customers and strengthen its research and development in this area. By supporting its customers with its specific, customized solutions and continually investing in research and development, Codexis positions itself as a leading provider of enzyme and protein engineering technologies.

What is the Codexis dividend?

Codexis pays a dividend of 0 USD distributed over payouts per year.

How often does Codexis pay dividends?

The dividend cannot currently be calculated for Codexis or the company does not pay out a dividend.

What is the Codexis ISIN?

The ISIN of Codexis is US1920051067.

What is the Codexis WKN?

The WKN of Codexis is A0Q2S4.

What is the Codexis ticker?

The ticker of Codexis is CDXS.

How much dividend does Codexis pay?

Over the past 12 months, Codexis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Codexis is expected to pay a dividend of 0 USD.

What is the dividend yield of Codexis?

The current dividend yield of Codexis is .

When does Codexis pay dividends?

Codexis pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Codexis?

Codexis paid dividends every year for the past 0 years.

What is the dividend of Codexis?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Codexis located?

Codexis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Codexis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Codexis from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Codexis pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Codexis in the year 2023?

In the year 2023, Codexis distributed 0 USD as dividends.

In which currency does Codexis pay out the dividend?

The dividends of Codexis are distributed in USD.

All fundamentals about Codexis

Our stock analysis for Codexis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Codexis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.